The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a Blanket Purchase Agreement to Progenics Pharmaceuticals Inc. for PYLARIFY products and services. The single award BPA, valued at over $1.3 million, was issued on July 15, 2022 against the Pharmaceuticals and Drugs Federal Supply Schedule master contract for the period of July 15, 2022 through June 14, 2024. Performance will take place in New York, New York.
The BPA calls authorize the delivery of PYLARIFY, a radiopharmaceutical used in positron emission tomography imaging to aid in the detection and localization of prostate cancer. Firm fixed pricing is established for two BPA call periods, from July 15, 2022 to July 14, 2023 valued at $1,381,605.44, and from July 15, 2023 to June 14, 2024 valued at $1,324,175.04. As the prime contractor, Progenics Pharmaceuticals will provide the contracted products and services to support diagnostic imaging services for veterans treated by the VA network, advancing their efforts to accurately diagnose and manage prostate cancer.
No subcontractors or set-asides were specified. The BPA was competitively awarded off the GSA Pharmaceuticals and Drugs schedule in accordance with federal procurement regulations to meet the network's projected demand for prostate cancer radiopharmaceuticals.
Generated 1/4/24, 5:28 PM